10 results about "Non malignant" patented technology

This disclosure provides: (i) a method of using an anticeramide antibody or an antigen-binding fragment thereof to improve hematopoietic stem cell transplantation for the treatment of various non-malignant and malignant diseases; and (ii) a composition for such treatment.

The present invention relates to means and methods to prevent and / or treat Epstein-Barr virus (EBV) and EBV-induced diseases, such as EBV infection, infectious mononucleosis (IM), malignant or non-malignant post-transplant lymphoproliferative disorder (PTLD) and other EBV-associated diseases. In particular, the invention provides a SQAPLPCVL peptide that can be used in a treatment or a method of treatment to induce an EBV-specific immune response in a subject. The SQAPLPCVL can be used in a treatment or method of treatment as a vaccine against EBV and EBV-induced diseases. It is preferred herein that Epstein-Barr virus (EBV) and / or EBV-induced diseases are prevented.

It has been discovered that differential methylation in DNA can be used to distinguish between malignant and non-malignant skin lesions. Seven genes, 3 that are hypermethylated in melanoma, 1 that is hypermethylated in melanocytes and remains methylated in melanoma, and 3 that are hypermethylated in all tissues are provided as biomarkers. The panel demonstrates a 93% sensitivity, 97% specificity and an AUC of 95% in distinguishing between melanoma and benign lesions. Thus provided herein are melanoma biomarkers and methods of detecting them and using them to diagnose and guide treatment of subjects with the same, and monitor melanoma tumor dynamics during and after treatment.

Immunotherapeutic Monoclonal Antibody Complexes or Conjugates (IMAC) comprising readily accessible antibodies designed and approved for clinical use are provided using a one-step method that combines killing of existing cancer cells in parallel with induction of long-lasting anti-cancer vaccination. Methods for their use, alone or in combination with cancer killer cells including intentionally mismatched donor T cells, NK cells concomitantly with additional anti-cancer or immune activating agents, or activation of patient's own immune system for personalized treatment of cancer and elimination of undesirable non-malignant cells are also provided. In addition, treatment method based on IMAC can be applied for in vivo vaccination against cancer using an existing malignant lesion as internal anti-cancer vaccine by engagement of patients antigen presenting cells for induction of long-lasting anti-cancer vaccination in situ against residual or recurrent disease.

Immunotherapeutic Monoclonal Antibody Complexes or Conjugates (IMAC) comprising readily accessible antibodies designed and approved for clinical use are provided using a one-step method that combines killing of existing cancer cells in parallel with induction of long-lasting anti-cancer vaccination. Methods for their use, alone or in combination with cancer killer cells including intentionally mismatched donor T cells, NK cells concomitantly with additional anti-cancer or immune activating agents, or activation of patient's own immune system for personalized treatment of cancer and elimination of undesirable non-malignant cells are also provided. In addition, treatment method based on IMAC can be applied for in vivo vaccination against cancer using an existing malignant lesion as internal anti-cancer vaccine by engagement of patient's antigen presenting cells for induction of long-lasting anti-cancer vaccination in situ against residual or recurrent disease.

The present invention provides gene or RNA therapeutic vectors for use in the treatment of non-malignant CNS disorders, which are to be injected into the pons by convection-enhanced delivery (CED). The invention also provides a method for treating non-malignant CNS disorders, comprising injecting a gene or RNA therapeutic vector into the pons of a subject in need (CED), and a method for distributing a gene therapy agent throughout the nervous system, wherein a viral vector transported anterograde and retrogradely is injected into the pons and middle cerebellar peduncle of a subject from a cannula inserted from the cerebellum and middle cerebellar peduncle into the pons.

Various methods of treating a disease or condition, such as cancer, autoimmune disease, or any disease involving cellular proliferation are presented herein comprising administering to the subject an effective amount of an HPDL inhibitor compound or pharmaceutical composition as described herein.

There is described herein methods for assessing survival risk of a human subject with haematological cancer or an age-related non-malignant disease. The method comprises analysis of at least 1000 of the 31744 differentially methylated regions (DMRs) set forth in Table 1 by determining an epigenetically stable loci (ESL) profile based on the methylation status of the at least 1000 DMRs; and categorizing the subject as having either low survival risk or high survival risk, each being associated with high DNA methylation instability (DMI) or low DMI respectively, wherein the subject has high DMI if the ESL profile has methylated DMRs exceeding a predetermined threshold and the subject has low DMI if the ESL profile has methylated DMRs below the predetermined threshold.

An orally active, brain penetrant first-in-class small molecule midkine inhibitor for use in the treatment of triple-negative breast cancer, brain tumors (including glioblastoma, medulloblastoma, and NF1-mutant optic pathway gliomas), ovarian and endometrial cancers, lung cancer, as well as gynecologic non-malignant conditions such as endometriosis, uterine fibroids, and preterm birth, in which tumor cells and / or pathological cells exhibit heightened midkine signaling and express multiple midkine receptors.

The invention provides methods, compositions, and combinations for treating cancer or a non-malignant disease or condition in which αv and / or α5 (e.g., α5β1 ) integrin is expressed or implicated in pathogenesis or progression. The methods include administration of a bispecific antibody that specifically binds αv integrin and α5 (e.g., α5β1 ) integrin and a Src inhibitor to provide treatment for the cancer or non-malignant disease or condition.